PANAJI
Glenmark Pharmaceuticals earlier this week attracted extensive media attention after it launched its first fixed-dose combination (FDC) to treat Type 2 diabetes in adults with comorbidities which the company with much of its production facilities in Goa said is the first drug of its kind in India.
It combines three medications to help improve glycemic control in diabetics, it said, adding that the medication will be sold under the ‘Zita DM’ brand name at a price of Rs 14 per tablet.
The triple medication drug contains teneligliptin, dapagliflozin and metformin SR, and will help adult diabetics with co-morbidities and high HbA1c and those who need to take teneligliptin and dapagliflozin as separate drugs.
The new ‘Zita DM’ pill’s dosage will be one a day.
Glenmark Pharmaceuticals is Mumbai headquartered and promoted by the Saldanha family which traces roots to Saligao.
